For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
MK-677 (ibutamoren mesylate) is a non-peptide, orally active agonist of the ghrelin receptor (GHS-R1a) that stimulates endogenous GH and IGF-1 secretion. It is the only oral GH secretagogue with substantial published human trial data, including a 2-year, double-blind, placebo-controlled RCT (Nass et al. 2008, Annals of Internal Medicine, n=65). That trial showed significant FFM preservation and GH axis restoration in older adults, with meaningful metabolic liabilities: worsened insulin sensitivity, increased fasting glucose, and no functional strength improvement. A Phase 2b hip fracture trial (Adunsky 2011, n=123) was terminated early for a congestive heart failure signal. An Alzheimer's disease trial (Sevigny 2008, n=563) showed zero cognitive benefit despite a 72.9% IGF-1 increase. The same molecule is now in Phase 3 pediatric GHD development as LUM-201 (Lumos Pharma), with Phase 2 data showing 8.2 cm/yr height velocity comparable to rhGH.
MK-677 is technically not a peptide. It is a non-peptide spiropiperidine small molecule (MW 528.67 g/mol) that mimics ghrelin by agonizing GHS-R1a. Its inclusion in this research series is appropriate because it shares the GH secretagogue receptor pathway with ipamorelin and GHRP-6, because it is the most clinically studied oral GH secretagogue in humans, and because it is widely used in the same research contexts as injectable GH secretagogue peptides. That said: the chemistry is different, the pharmacokinetics are fundamentally different, and the risk profile has some distinctions from injectable peptide GHRPs.
The oral bioavailability is MK-677's defining pharmacological property. All injectable GH secretagogues (ipamorelin, GHRP-6, sermorelin, CJC-1295, tesamorelin) require subcutaneous injection. MK-677 is taken orally once daily. This single characteristic explains its widespread use and the depth of its clinical evidence base: it is far easier to administer in long-duration trials and in research settings than injectable alternatives. The Chapman 1996 and Nass 2008 trials are larger and longer than any human efficacy data available for any injectable GHRP reviewed in this series.
The congestive heart failure signal from the Adunsky 2011 hip fracture Phase 2b trial is the most important safety fact to front-load: 4 of 62 patients in the ibutamoren arm (6.5%) developed CHF vs. 1 of 61 patients on placebo (1.7%), leading to early termination. The FDA explicitly cites this when categorizing ibutamoren's risk profile. The patients were elderly hip fracture patients, a high-risk cardiac population -- but the signal is real, FDA-documented, and cannot be minimized. Ibutamoren may cause or precipitate heart failure through fluid retention mechanisms in patients with compromised cardiac reserve.
The Alzheimer's disease trial (Sevigny 2008, n=563, 12 months) is an underappreciated cautionary data point: IGF-1 was elevated 72.9% -- a massive pharmacological response confirming target engagement -- but there was zero clinical effect on AD progression. This matters beyond the specific AD indication. It demonstrates that elevating IGF-1 does not automatically translate to clinical benefit in neurodegenerative disease, and should temper enthusiasm for cognitive and neuroprotective claims more broadly.
MK-677 was developed by Merck Research Laboratories in the early 1990s as part of a program to identify orally bioavailable small molecules that could stimulate endogenous GH secretion. The design goal was to produce an oral alternative to injectable rhGH for conditions involving GH deficiency -- particularly pediatric GHD and age-related GH decline.
The compound is derived from benzolactam analogs originally modeled on GHRP-6 chemistry. Through iterative chemical modification, Merck's team identified a spiropiperidine compound (designated L-163,191, later MK-677) with potent GHS-R1a agonism and, critically, sufficient oral bioavailability and metabolic stability to be active after oral administration. This was a non-trivial pharmaceutical accomplishment: most peptide GH secretagogues are rapidly degraded in the GI tract.
MK-677's oral bioavailability is approximately 60 to 70% with a plasma half-life of approximately 24 hours, supporting once-daily oral dosing. These pharmacokinetics enable sustained, tonic elevation of GH axis activity rather than the discrete pulsatile GH bursts produced by short-acting injectable GHRPs. This is both a therapeutic feature (consistent GH axis activation for sustained IGF-1 elevation) and a mechanistic consideration (it may blunt the physiological pulsatility the GH axis normally uses for receptor sensitivity calibration).
Merck discontinued MK-677 development around 1999 following Phase 3 pediatric GHD results that were insufficient to justify continued development. The compound was subsequently acquired by ConjuChem and later by Lumos Pharma (formerly OcuSense), which relicensed it as LUM-201 and developed a patient selection strategy using a Predictive Enrichment Marker (PEM) -- identifying moderate rather than severe GHD patients with intact pituitary GH secretory capacity, for whom a secretagogue can work. Phase 2 data from OraGrowtH210 and OraGrowtH212 met all primary and secondary endpoints in 2023, and Phase 3 (NCT06948214) is actively enrolling.
MK-677 agonizes GHS-R1a (growth hormone secretagogue receptor type 1a), also known as the ghrelin receptor, via a non-peptide small molecule mechanism that mimics the endogenous hormone ghrelin. GHS-R1a activation at the anterior pituitary initiates Gq/11-coupled signaling: activation of phospholipase C, generation of inositol-1,4,5-trisphosphate (IP3), and release of intracellular calcium from the endoplasmic reticulum. This calcium signal triggers exocytosis of GH-containing secretory granules from anterior pituitary somatotrophs.
Simultaneously, MK-677 acts on GHS-R1a receptors in the hypothalamic arcuate nucleus, stimulating GHRH neuron activity and suppressing somatostatinergic tone. This dual pituitary plus hypothalamic action amplifies GH secretion beyond what pituitary-only GHS-R1a activation would produce. The hypothalamic component is one reason why MK-677's GH-stimulating potency in humans exceeds that of some injectable GHRPs at equivalent receptor occupancy.
The ghrelin receptor is also expressed in the orexigenic NPY/AgRP neurons of the hypothalamic arcuate nucleus, mediating ghrelin's appetite-stimulating effects. MK-677's activation of these neurons is responsible for the significant increase in appetite that is one of its most consistent side effects -- this is mechanistically unavoidable with full GHS-R1a agonism and distinguishes MK-677 from ipamorelin's more selective cortisol-free profile.
GH release through GHS-R1a remains subject to somatostatin-mediated negative feedback, preserving the physiological ceiling on GH elevation. The Nass 2008 study confirmed that GH pulsatility is maintained during chronic MK-677 treatment -- increased pulse amplitude (GH per pulse) rather than increased pulse frequency, consistent with somatostatin modulation of pulse shape. Sustained GH elevation from once-daily MK-677 drives hepatic IGF-1 synthesis, mediating downstream anabolic, lipolytic, and tissue-repair effects. IGF-1 increases of 40 to 100% above baseline are consistently demonstrated across multiple MK-677 human trials.
Nass 2008 primary results (n=65, 12-month primary endpoint): Fat-free mass in the placebo group declined by a mean of 0.5 kg (95% CI, minus 1.1 to 0.2) while FFM increased 1.1 kg (95% CI, 0.7 to 1.5) in the MK-677 group (P less than 0.001, MK-677 vs. placebo). Body cell mass as reflected by intracellular water decreased 1.0 kg with placebo but increased 0.8 kg with MK-677 (P=0.021). Abdominal visceral fat (AVF) did not significantly decrease -- the co-primary visceral fat endpoint was not met. Body weight increased approximately 1.4 kg more with MK-677 than placebo.
GH axis restoration: 24-hour mean GH increased 1.8-fold from baseline (P less than 0.001) and IGF-1 increased 1.5-fold (P less than 0.001), restoring levels to the young-adult range in most subjects. GH pulsatility was maintained throughout -- increased amplitude per pulse, not frequency, consistent with preserved somatostatin modulation.
What did not improve: isokinetic muscle strength did not improve, functional performance measures did not improve, and quality of life scores did not improve despite the FFM increase. Cortisol increased 47 nmol/L. Fasting blood glucose and insulin sensitivity worsened. Bone mineral density changes were consistent with increased remodeling (femoral neck BMD declined at 12 months, a pattern typical of early GH axis stimulation that may reverse with longer treatment).
Svensson 1998 (n=24 obese males, 8 weeks): IGF-1 increased approximately 40%, FFM increased significantly by DEXA. Total and visceral fat did not significantly change. Basal metabolic rate increased at 2 weeks but not at 8 weeks. Glucose tolerance impaired on oral glucose tolerance test.
Two-year exploratory analysis (Nass 2008): The FFM advantage of MK-677 over placebo was maintained through 24 months. Fasting blood glucose did not significantly worsen between 12 and 24 months, suggesting some metabolic accommodation, though the worsening from baseline persisted.
The Nass 2008 RCT is the anchor clinical study for MK-677 in adults and one of the most rigorous GH secretagogue trials in humans. The FFM preservation finding is clinically meaningful -- preventing age-related lean mass loss is a legitimate therapeutic target. However, four elements of the result limit interpretation. First, visceral fat did not decrease despite GH and IGF-1 restoration, which is the opposite of what tesamorelin achieves via the same GH axis. Second, FFM gains did not translate to strength or functional improvement, raising the question of whether the lean mass increase reflects contractile tissue or fluid redistribution. Third, insulin sensitivity worsened, creating an unfavorable metabolic tradeoff. Fourth, the sample size and 2-year duration are insufficient to evaluate functional endpoints or long-term safety in this context. The Nass 2008 editorial in the same journal issue was titled: 'Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time.' That assessment remains accurate.
Adunsky 2011 primary endpoint: Stair climbing power increased 12.5 W in MK-677 group (95% CI, minus 10.95 to 35.88; P=0.292) -- not significant. Gait speed improved significantly (difference +0.7; P=0.011). Several other functional performance measures showed no improvement. Fewer falls in MK-677 group (P=0.096, borderline non-significant). IGF-1 increased 51.4 ng/ml in treated patients vs. placebo (P less than 0.001).
Critical safety finding: 4 patients in the ibutamoren group (6.5%) developed congestive heart failure vs. 1 in the placebo group (1.7%). The trial was terminated early due to this CHF safety signal. The authors concluded MK-677 has an unfavorable safety profile in this patient population. Note: The CHF rate was higher in the MK-677 arm and the groups had higher baseline blood pressure in the MK-677 arm, introducing some uncertainty about whether CHF was entirely drug-related vs. baseline imbalance. However, the absolute rate (6.5%) and the FDA's subsequent documentation of this signal both confirm the clinical concern.
Context from Bach 2004 (n=161, predecessor trial): Serious adverse events were similarly distributed between groups. More patients discontinued due to clinical adverse events in the ibutamoren group (P less than 0.05). No CHF signal was identified, but more thromboses were reported in the ibutamoren group (not believed drug-related). The two trials together paint a picture of an unfavorable tolerability profile in frail elderly patients with hip fracture, with the 2011 trial producing the definitive CHF signal.
This trial represents the defining safety event for MK-677 in clinical development. The congestive heart failure signal -- 4 cases vs. 1 on placebo in a trial of 123 patients -- terminated the study and is what the FDA cites when documenting ibutamoren's risk profile. The population was elderly hip fracture patients who already carried elevated cardiac risk, and the mechanism of CHF (fluid retention from GH axis activation in patients with limited cardiac reserve) is biologically coherent. The efficacy picture was also unfavorable: functional outcomes were largely not met. MK-677 does not have a viable future in frail elderly populations based on current data.
Target engagement was confirmed: patients receiving MK-677 showed a 60.1% increase in serum IGF-1 at 6 months and a 72.9% increase by 12 months. This is the largest IGF-1 elevation documented in any published MK-677 trial, demonstrating robust pharmacological action on the intended target.
Clinical efficacy was zero: no significant difference between MK-677 and placebo on the primary CIBIC-plus endpoint. No significant difference on ADAS-Cog, ADCS-ADL, or CDR-sum of boxes. Of 563 patients randomized, 416 completed 12-month assessments.
Post-hoc subgroup: Patients without the ApoE epsilon-4 allele showed a trend toward benefit in some secondary measures. This finding was hypothesis-generating and not pre-specified, and should be viewed as exploratory.
More patients in the MK-677 group experienced increased blood glucose (15.4% vs 4.6% placebo) and HbA1c increases, consistent with the metabolic liability documented in other trials.
The Sevigny 2008 Alzheimer's trial is an underappreciated cautionary data point for the entire GH secretagogue research program. IGF-1 was elevated by nearly 73% -- an enormous pharmacological response confirming that the drug did exactly what it was supposed to do -- and there was absolutely no clinical benefit for Alzheimer's disease. The investigators were direct in their conclusion: 'The lack of clinical efficacy of MK-677 despite a robust IGF-1 increase argues that the age-related decline of the somatotropic axis is not contributing to the pathways underlying AD or its clinical manifestation.' This matters beyond the specific AD indication. It is a clear demonstration that elevating GH and IGF-1 does not automatically produce cognitive, neuroprotective, or functional clinical benefits, and should moderate any claims in those domains.
OraGrowtH210 (n=82, primary results): The 1.6 mg/kg/day dose achieved AHV of 8.2 cm/yr at 6 months and 8.0 cm/yr at 12 months. Historical reference for moderate PGHD children on injectable rhGH: 8.3 to 8.6 cm/yr. The 6-month and 12-month AHV were within the targeted 2 cm/yr non-inferiority margin of the active rhGH comparator arm. All prespecified primary and secondary endpoints were met. 24-month data from a combined subset of 10 subjects showed sustained AHV effect from year 1 to year 2.
OraGrowtH212 (n=24, PK/PD): LUM-201 achieved expected AHV while exposing patients to only 20% of the GH concentration produced by injectable rhGH. This was achieved through LUM-201's pulsatile mechanism -- restoring endogenous GH secretion patterns rather than imposing supraphysiological GH levels. IGF-1 values remained within 2 SD of mean throughout, contrasting with injectable rhGH which raises circulating GH 4 to 5 times normal pediatric ranges.
Predictive Enrichment Marker (PEM) strategy: Two markers identify likely responders to LUM-201: baseline IGF-1 greater than 30 ng/mL and peak GH response of 5 ng/mL or more to single-dose LUM-201. PEM-positive status enriches for LUM-201 response; PEM-negative status enriches for rhGH response. This stratification is the key intellectual contribution of Lumos Pharma's development program -- it explains why Merck's original broad-indication development produced mixed results (severe GHD patients cannot respond to a secretagogue because their pituitary cannot secrete adequate GH).
Safety in pediatric trials: No serious adverse events. No meaningful safety signals in laboratory values, adverse events, or ECG data through March 2024. Most common adverse events: increased appetite, extremity pain, arthralgia. No CHF signal in children.
The LUM-201 Phase 2 program is the most promising active development pathway for this molecule, and the PEM strategy is a genuine scientific advance over the original Merck development approach. The data show that moderate PGHD children with intact pituitary function can achieve comparable height velocity to injectable rhGH while exposed to only 20% of the GH burden -- a clinically meaningful benefit for a pediatric population that currently requires daily injections throughout childhood. The clean pediatric safety profile to date is reassuring, though it reflects a younger, healthier, and non-cardiac-risk population that cannot be extrapolated to adult applications.
Murphy 2001 (n=292, 18 months): MK-677 with or without alendronate markedly increased IGF-1 by 39% and 45% respectively (P less than 0.05). MK-677 alone increased bone formation markers: osteocalcin up 22% and urinary NTx up 41% (P less than 0.05 vs. placebo) -- indicating increased bone turnover. The combination of MK-677 plus alendronate mitigated the reduction in bone formation expected with alendronate alone and increased femoral neck BMD more than alendronate alone.
Bone formation interpretation: MK-677 initially increases both bone formation and resorption markers (the remodeling acceleration effect seen with GH axis stimulation). Nass 2008 noted that femoral neck BMD declined at 12 months with MK-677, consistent with the early remodeling phase. Longer GH replacement studies consistently show that BMD increases after 12 to 18 months as formation eventually exceeds resorption -- but no long-duration MK-677 BMD study with fracture endpoints exists.
The combination MK-677 plus alendronate data from Murphy 2001 is mechanistically interesting: it suggests that coupling GH axis stimulation (formation-promoting) with anti-resorptive therapy (alendronate) may provide additive BMD benefit. This was not developed further.
Moderate-Low. MK-677 increases bone turnover and has shown bone remodeling activity in controlled trials. The 18-month combination therapy data from Murphy 2001 shows a plausible mechanistic contribution to BMD preservation. However, no fracture endpoint trial exists, no long-duration BMD superiority trial was completed, and the early BMD decline in the Nass 2008 trial is a confounding signal for shorter-duration use. This remains a mechanistically coherent but clinically underdeveloped application.
Copinschi 1996 (7-day MK-677 study): REM sleep increased significantly with MK-677. Stage 4 (slow-wave) sleep was also increased. GH secretion during sleep was augmented. This is mechanistically expected: ghrelin and GHS-R1a agonists have well-established sleep-promoting effects, and the majority of endogenous GH secretion occurs during slow-wave sleep. Augmenting the GH axis during sleep is consistent with improved sleep architecture.
Multiple clinical trial participants in the Nass 2008 cohort reported improved sleep quality subjectively, though this was not a primary endpoint and was not formally scored with validated sleep instruments. The increase in slow-wave sleep with GH axis stimulation is consistently observed across GHRH, GHRP, and GHS-R1a agonist classes, suggesting a genuine class effect rather than an MK-677-specific finding.
Low to Moderate. The Copinschi 1996 data shows REM and stage 4 sleep augmentation with short-term MK-677 in a controlled study. The mechanism is coherent and supported by ghrelin/GHS-R1a sleep biology. Improved sleep quality is one of the most consistently reported subjective benefits of MK-677 in research settings and is mechanistically plausible. However, no primary-endpoint sleep RCT using validated instruments has been published for long-term MK-677 use. This application is better supported than most GH secretagogue sleep claims due to direct human sleep architecture data, but the clinical significance for chronic use remains uncharacterized.
Oral compound. Clinical trials used 25mg daily.
MK-677 (ibutamoren mesylate) is not FDA-approved and is illegal to sell as a dietary supplement in the US. The FDA has issued warning letters to companies marketing ibutamoren illegally. Products marketed as research chemicals or dietary supplements containing ibutamoren are unapproved drugs. The WADA prohibition applies to sport use. DoD prohibition applies to service members. For legitimate research: pharmaceutical-grade ibutamoren mesylate for in vitro or preclinical use is available from specialty chemical suppliers. The only currently active pharmaceutical development program is LUM-201 by Lumos Pharma for pediatric GHD (NCT06948214). Adult applications currently have no active pharmaceutical sponsor. Patients or practitioners considering MK-677 for adult use should note the FDA-documented CHF risk in patients with cardiac vulnerability, the consistent insulin resistance and glucose worsening across multiple trials, and the absence of functional benefit in the best available adult RCT.
MK-677 vs. ipamorelin (same receptor target, different chemistry): Both agonize GHS-R1a. MK-677 is oral; ipamorelin requires injection. MK-677 has multiple published human RCTs including 2-year data; ipamorelin's only human efficacy RCT (postoperative ileus) failed its primary endpoint. MK-677 causes significant appetite increase through GHS-R1a orexigenic pathway; ipamorelin's selectivity profile reportedly avoids this. MK-677 has a documented CHF signal in elderly; ipamorelin's safety data in humans is extremely limited. For human evidence quantity: MK-677 is categorically superior. For safety profile in the available data: the comparison is unresolved, not ipamorelin-favorable.
MK-677 vs. tesamorelin (FDA-approved GH axis comparator): Tesamorelin is FDA-approved for HIV lipodystrophy with Phase 3 data (n=806) showing 15 to 20% selective visceral fat reduction -- a specific clinically meaningful endpoint. MK-677 did not reduce visceral fat in Nass 2008 despite robust GH/IGF-1 elevation. Mechanistic reason: GHRH analogs like tesamorelin produce more physiological pulsatile GH release that may be more effective for visceral adipose tissue. For visceral fat reduction: tesamorelin evidence is categorically stronger. For systemic GH axis restoration: MK-677 produces larger IGF-1 increases with oral convenience.
MK-677 vs. sermorelin (GHRH analog comparison): Sermorelin was FDA-approved from 1990 to 2004 with a well-characterized safety record. It has more clinical pedigree for anti-aging applications than MK-677, smaller IGF-1 elevations, and no CHF signal. MK-677 has larger hormone effect sizes and published 2-year RCT data sermorelin lacks for aging. Neither is FDA-approved for aging applications. Both have metabolic liabilities (less severe with sermorelin due to smaller GH elevations).
MK-677 has the most extensive human safety database of any non-approved GH secretagogue, but that database includes two critical signals that must be front-loaded.
Signal 1 -- Congestive heart failure (Adunsky 2011, Phase 2b hip fracture, n=123): Four patients in the ibutamoren arm (6.5%) developed CHF vs. 1 in the placebo arm (1.7%). The trial was terminated early. The FDA explicitly cites this when documenting ibutamoren's safety concerns. The patients were elderly hip fracture patients -- a high-risk population for fluid retention and cardiac decompensation -- and the CHF rate may have been partly attributable to higher baseline blood pressures in the MK-677 arm. A separate earlier hip fracture trial (Bach 2004, n=161) did not show the same CHF rate, introducing some uncertainty about the signal's reliability. Nevertheless: CHF developed in a randomized controlled trial on MK-677, the FDA has documented this, and the risk is biologically plausible through GH-mediated sodium and water retention.
Signal 2 -- Glucose and insulin metabolism: Across multiple trials, MK-677 consistently worsens insulin sensitivity and raises fasting blood glucose. Chapman 1996 found 25 mg/day increased fasting glucose from 5.4 to 6.8 mmol/L at 4 weeks. Nass 2008 found increased fasting blood glucose and reduced insulin sensitivity at 12 months. Adunsky 2011 found more patients with increased blood glucose (6.5% vs 1.7% placebo) and increased HbA1c (4.8% vs 0% placebo). Sevigny 2008 found more patients with increased blood glucose (15.4% vs 4.6% placebo) and HbA1c differences. This is mechanistically expected -- GH is counter-regulatory to insulin -- but it is consistent and clinically meaningful. MK-677 should be used with extreme caution or avoided in patients with diabetes, prediabetes, or metabolic syndrome.
Other established adverse effects: Increased appetite (the most commonly reported side effect -- 67% vs 36% on placebo in Nass 2008); fluid retention and peripheral edema; mild cortisol elevation (transient in some studies, more sustained in others); joint pain and arthralgia (common in LUM-201 pediatric data). MK-677 is prohibited in sport under WADA (GH secretagogues). It is illegal to sell as a dietary supplement in the US. Long-term cancer risk from chronic IGF-1 elevation has not been formally studied and remains a theoretical concern in line with the broader IGF-1 cancer biology literature.
MK-677 occupies a genuinely unusual position in the GH secretagogue landscape: it has more published human trial data than any non-approved GH secretagogue reviewed in this series, and its oral bioavailability is a pharmacologically real and clinically meaningful advantage over all injectable alternatives. The Nass 2008 2-year RCT in Annals of Internal Medicine is a landmark study. No other GH secretagogue has data of this quality and duration in healthy older adults.
And yet the honest totality of the evidence base is sobering. The primary FFM benefit did not translate to functional improvement. The visceral fat co-primary endpoint was not met. Insulin sensitivity consistently worsens. A Phase 2b trial was terminated for congestive heart failure. A large well-run trial in Alzheimer's disease showed zero benefit despite near-73% IGF-1 elevation. Merck discontinued the compound after mixed Phase 3 results. The body of published data is large, but it includes multiple definitive negatives alongside the positive body composition signal.
The clearest remaining pathway is LUM-201 in moderate pediatric GHD -- the application most suited to a compound that requires intact pituitary function to work, in a population without cardiac risk that avoids the CHF concern, for an indication (avoiding daily injections in children) where the oral route is a genuine unmet need. Phase 3 data is pending.
For adult anti-aging and body composition applications: the evidence supports that MK-677 increases GH and IGF-1, preserves FFM in older adults, and improves sleep architecture. It does not support that these changes produce meaningful functional, cognitive, or quality-of-life benefits at the doses and durations studied. The insulin resistance and glucose liability is a real tradeoff that must be weighed in any individual decision. The CHF signal in frail elderly patients requires clinical screening and caution in anyone with cardiac disease or significant cardiac risk factors.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use